INTRODUCTION
Adoptive transfer of T cells is a therapeutic approach used to target both solid tumors and leukemia. T-cell receptor (TCR) gene transfer is an attractive strategy, which enables rapid engineering of large numbers of T cells with defined antigen-specificity. Different studies have shown the effectiveness of TCR transfer, both in vitro [1] [2] [3] [4] [5] and in vivo. 6, 7 Recently, the in vivo efficacy of adoptively transferred TCR transduced (td) T cells was demonstrated in melanoma and synovial cell sarcoma patients. [8] [9] [10] TCR gene transfer poses different safety issues, which might warrant the inclusion of a suicide gene. First, high affinity TCRs might pose the risk of on-target toxicity. Recently, it has been described that the administration of high affinity chimeric antigen receptor-td T cells directed against tumor associated antigens also recognized healthy tissue expressing lower quantities of the antigen, resulting in on-target toxicity. 11, 12 Likewise, the administration of high affinity TCR td T cells specific for MART-1 or CEA resulted in on-target autoimmune destruction that required treatment. 8, 13 Furthermore, in the case of unexpected off-target reactivity due to the formation of mixed TCR dimers composed of endogenous TCR chains pairing with introduced TCR chains, 14, 15 inclusion of a suicide gene as a safety switch can abrogate toxicity directed against healthy tissue.
In our laboratory, we have recently characterized allo-major histocompatibility complex restricted preferentially expressed antigen in melanoma (PRAME)-specific T cells. PRAME was identified as a human melanoma antigen, but has since been found overexpressed on many other solid tumors and hematologic malignancies as well. [16] [17] [18] [19] PRAME expression on normal tissues is either low or absent, with exception of the immunopriviliged testis, where an intermediately high PRAME expression has been found. 16, 19, 20 The allo-major histocompatibility complex restricted PRAME-specific T cells were derived from an immune response in a patient transplanted over a human leukocyte antigen (HLA)-A2 mismatch. 21 These T cells demonstrated single peptide-specific high-avidity recognition of the PRAME-derived peptide SLLQHLIGL (SLL), one of the previously identified PRAME eptitopes, 22 and reactivity of the T cells correlated strictly with PRAME expression. The allo-HLA restricted PRAME-specific T-cell clone displayed high reactivity against melanoma and leukemic cell lines. No reactivity was observed against various different healthy cell types, derived from different tissues, with the exception of low reactivity directed against mature dendritic cells and proximal tubular epithelial cells. 21 As the significance of the on-target reactivity against mature dendritic cells and proximal tubular epithelial cells is unknown, inclusion of a safety switch might be warranted.
Several suicide genes or safety switches have been reported. Herpes simplex virus thymidine kinase (HSV-tk) is a wellestablished suicide gene that has been successfully used to control graft versus host disease following donor lymphocyte infusion after allogeneic stem cell transplantation. [23] [24] [25] However, in immunocompetent patients gene modified lymphocytes rapidly disappeared due to the induction of HSV-tk-specific immunity. 26, 27 Another disadvantage is the use of ganciclovir to eliminate HSV-tk modified T cells, as ganciclovir is first line therapeutic agent to treat cytomegalovirus reactivations, a common complication in patients after allogeneic stem cell transplantation. Recently, the efficacy of inducible Caspase 9 (iCasp9) as a suicide switch was demonstrated. 28 Upon exposure to a synthetic dimerizing drug, iCasp9 becomes activated and leads to the rapid death of cells expressing this construct. Patients were treated with iCasp9 modified donor lymphocyte infusion after haploidentical stem cell transplantation. A single dose of dimerizing drug was demonstrated to eliminate more than 90% of the modified T cells within 30 min after administration and ended the observed graft versus host disease without recurrence. A potential downfall of iCasp9 is that it uses a reagent that is not commercially available and that an additional selection marker is required.
Another well-studied suicide gene is the CD20 cell surface molecule. 29, 30 CD20 is a transmembrane calcium channel that is suggested to have a role in B-cell activation, proliferation and differentiation. It is first expressed on pre-B-cells and persists until later in differentiation, but is absent on terminally differentiated plasma cells. As CD20 is already expressed on the cell surface of B-cells, it is unlikely that CD20 expressed on T cells will be immunogenic. We have demonstrated that human CD20 may be used as a safety switch in adoptive immunotherapy without affecting normal antigen-specific T-cells functions, 31 and might double as a selection marker as well. This double function as both a suicide switch and cell surface expressed selection marker is especially beneficial when additionally a TCR or another therapeutic gene is introduced. Rituximab (RTX) is a therapeutic anti-CD20 antibody, which is widely used in the clinic, and upon ligation of CD20 triggers various effector mechanisms, including complement-dependent cytotoxicity (CDC).
A crucial factor for the success of the CD20 safety switch is profound coexpression of both CD20 and the introduced TCR. If td T cells highly expressing the introduced TCR, but inefficiently expressing the CD20 safety switch are adoptively transferred, this could result in unwanted toxicity that cannot be switched off. Previously, we have demonstrated that the expression of CD20 and the TCR in two separated constructs resulted in profound expression of both the CD20 as well as the introduced TCR. 32 However, transduction of two constructs leads to reduced transduction efficiency, and requires an extra selection step in vitro of the CD20 þ T cells to avoid the infusion of T cells that express the TCR but do not express CD20. To increase efficiency and assure solid coexpression of both the introduced TCR and CD20, the TCR a and b chains and CD20 gene sequences were linked with 2A sequences 33 in a single multi-cistronic vector. However, we observed that transduction of cells with a multicistronic vector encoding both TCRab-chains and CD20 resulted in impaired expression of particularly CD20.
To overcome this low coexpression, both the introduced TCR as well as CD20 were codon optimized. Here, we demonstrate that transduction with a codon optimized multi-cistronic vector encoding for both the PRAME-TCR and CD20 results in pronounced, concordant cell surface expression of both the TCR and CD20, whereas no single antigen-reactive TCR-positive cells were detected. Our data show that after RTX-induced CDC, CD20-positive cells are efficiently eliminated, resulting in the abrogation of PRAME-specific reactivity. In conclusion, for future clinical studies codon optimized CD20 can be a useful safety switch.
RESULTS AND DISCUSSION
Low coexpression of unmodified TCR and CD20 A crucial factor for the success of the CD20 safety switch in a multi-cistronic retroviral vector encoding for an antigen-specific TCR and CD20 is high cell surface expression and, in addition, concordant expression of both transgenes. Previously, we have demonstrated that the expression of CD20 and an antigen-specific TCR in two separated constructs resulted in profound expression of both the CD20 as well as the introduced TCR. 32 To increase efficiency and assure solid coexpression of both the introduced TCR and CD20, a single multi-cistronic vector was engineered, containing both an antigen-specific TCR and CD20 (HA2-TCR-CD20). However, we observed that transfer of this multi-cistronic vector into TCRab-deficient Jurkat 76 (J76) cells resulted in disconcordant expression, as B73% of TCR-positive J76 cells did not express CD20 (Figure 1a ). In addition, CD20 expression was very low (mean fluorescence intensity (MFI) ¼ 47). It was previously described that codon optimization of CD20 resulted in higher cell surface expression, 34 and we could reproducibly ( Figure 1f ) demonstrate a statistically significant (Po0.001) higher CD20 cell surface expression of codon optimized CD20 (CD20 CO ; Figure 1c ) versus unmodified CD20 ( Figure 1b ) td J76 cells. To ensure optimal TCR cell surface expression, the PRAME-TCR was codon optimized, resulting in high TCR cell surface expression (MFI ¼ 179) (PRAME-TCR CO -nerve growth factor (NGF)-R; Figure 1d ). For clinical purposes, we constructed a multi-cistronic vector encoding for codon optimized PRAME-TCR and CD20 (PRAME-TCR CO -CD20 CO ; Figure 1e ). As can be observed in Figure 1e , transfer of this retroviral construct into J76 cells resulted in high expression of both the PRAME-TCR (MFI ¼ 230) and the CD20 suicide switch (MFI ¼ 147). CD20 CO is efficiently expressed at the cell surface and can act both as a selection marker and suicide switch In TCRa-deficient J76 cells no competition for cell surface expression between introduced and endogenous TCR is present. To assess whether virus-specific T cells demonstrate efficient coexpression for the PRAME-TCR, as well as CD20, HLA-B7 restricted cytomegalovirus pp65-specific T cells derived from peripheral blood were isolated and td with the different constructs. One week after transduction, nonpurified T cells were analyzed for TCR and CD20 cell surface expression, as depicted in Figure 2a . Cell surface expression of codon optimized CD20 (MFI ¼ 782) was superior to cell surface expression of unmodified 
codon optimized PRAME-TCR coupled to NGF-R (PRAME-TCR CO -NGF-R; MFI TCR ¼ 179) or (e) codon optimized PRAME-TCR coupled to codon optimized CD20 (PRAME-TCR CO -CD20 CO CD20 (MFI ¼ 70). CD20 cell surface expression of PRAME-TCR CO -CD20 CO td pp65-specific T cells (MFI ¼ 165) was higher than CD20 td T cells, but lower than CD20 CO td T cells. The PRAME-TCR CO -CD20 CO T cells efficiently coexpressed the PRAME-TCR and CD20 and no single TCR-expressing cells were demonstrated, which indicates that codon optimization of the TCR and CD20 results in concordant expression of both transgenes. To confirm that CD20 can double as a selection marker, we isolated virus-specific T cells (BMLF-1, pp50) or total T cells from different individuals and transduced these T cells with PRAME-TCR CO -CD20 CO . Profound PRAME-TCR expression was observed for all the different PRAME-TCR CO -CD20 CO td T cells (Figure 2b) . The four different PRAME-TCR CO -CD20 CO td T cells were subsequently magnetic-activated cell sorting (MACS)-enriched based on their CD20 cell surface expression. After MACS-isolation T cells were checked using flowcytometry, put in culture and purity of the T cells was confirmed 1 week after an additional restimulation. As demonstrated in Figure 2c , all the positively isolated MACSfractions were highly enriched for CD20 expressing cells directly after sort. In addition, Figure 2d shows that after 1 week of expansion the T cells efficiently coexpressed CD20 and the PRAME-TCR, demonstrating that CD20 can be used as a selection marker. To study whether expression of the CD20 suicide switch of PRAME-TCR CO -CD20 CO td T cells was sufficient to result in CDC, td pp65-specific T cells ( Figure 2a) were either purified based on CD20 or NGF-R expression using flowcytometry, preincubated with Figure 2 . pp65-specific T cells transduced with a multi-cistronic PRAME-TCR CO -CD20 CO clinical vector demonstrate profound TCR and CD20 coexpression and can be eliminated by CDC. To study PRAME-TCR and CD20 coexpression, several virus-specific T cells and total T cells were transduced with PRAME-TCR CO -CD20 CO and analyzed using flowcytometry. (a) HLA-B7 restricted cytomegalovirus (CMV) pp65-specific T cells were isolated from a healthy individual, and transduced either with an empty vector (mock), unmodified CD20, CD20 CO or PRAME-TCR CO -CD20 CO . One week after transduction, pp65-specific T cells were analyzed for CD20 and TCR expression using anti-CD20 monoclonal antibodies (mAbs) and tetramers. A representative experiment out of two experiments performed with different HLA-B7 restricted CMV pp65-specific T cells is shown. medium or RTX followed by complement treatment, and CDC lysis was analyzed using flow cytometry ( Figure 3a) . As can be observed, no RTX-induced CDC was elicited in mock td or PRAME-TCR CO -NGF-R td T cells. T cells solely td with the CD20 suicide switch (CD20) demonstrated RTX-induced CDC of B40%. More efficient CDC was observed for CD20 CO td T cells (86%) and PRAME-TCR CO -CD20 CO td T cells (73%). These data demonstrate that the improved expression of CD20 in PRAME-TCR CO -CD20 CO td cells compared with unmodified CD20 td cells results in more efficient elimination of these td T cells.
To study whether RTX-induced CDC of PRAME-TCR CO -CD20 CO td cells correlated with abrogated PRAME-specific T-cells responses, we transduced purified pp65-specific T cells with different PRAME-TCR constructs and tested these cell lines directly 1 week after transduction without further purification. PRAME-TCR td T cells were tested against peptide loaded target cells (Figure 3b ) and PRAME-positive melanoma cell lines presenting endogenously processed antigen (Figure 3c ) after incubation with either medium or RTX followed by complement treatment. As only 4-5% of the pp65-specific T cells were transduced with PRAME-TCR CO -CD20 CO , elimination of td T cells would not result in measurable loss of pp65 antigen-specificity. In agreement with this, no measurable loss of pp65-specific interferon-gamma (IFN-g ) production was observed after RTX and complement treatment (Figure 4b ). When PRAME-TCR CO -CD20 CO td pp65-specific T cells were tested after RTX and complement treatment, a significant decrease in PRAMEspecific IFN-g responses were observed, both after stimulation with peptide pulsed target cells (Figure 3b) , as well as after stimulation with PRAME-expressing melanoma cells (Figure 3c ), whereas no loss of PRAME-specific IFN-g responses were observed after RTX treatment of PRAME-TCR-NGF-R td pp65-specific T cells. In conclusion, observation of CDC lysis correlated with loss of introduced PRAME-specific TCR reactivity.
RTX-induced elimination results in loss of T cells capable of inducing on-target toxicity
To more precisely investigate the efficiency of RTX-induced CDC, the residual activity of the RTX and complement treated PRAME-TCRco-CD20 CO td T cells were quantified. For this purpose, nonsorted PRAME-TCR CO -NGF-R and PRAME-TCR CO -CD20 CO td pp65-specific T cells were incubated either with medium or RTX followed by complement treatment, titrated down and tested for PRAME-specific IFN-g production ( Figure 4 ). To start with 5 Â 10 3 cells, the number of T cells tested was corrected for the transduction efficiency. Comparable PRAME-specific IFN-g responses were observed for both td pp65-specific T-cells populations without RTX and complement treatment (Figures 4a and c) . When RTX-incubated PRAME-TCR CO -CD20 CO td T cells were treated with complement, loss of PRAME-specific IFN-g responses were observed (Figures 4b and d) , both against PRAME peptide pulsed target cells (Figure 4b ) as well as against PRAME þ melanoma cells (Figure 4d) . Whereas no specific IFN-g production could be detected against PRAME þ melanoma cells after RTX and complement treatment (Figure 4d) , some residual IFN-g production could be observed against PRAME peptide pulsed target cells if 5000 td cells were tested (Figure 4b ). This residual IFN-g production was equal to IFN-g production of B123 untreated td T cells (Figure 4a) , indicating that at least 4800 T cells and thus 95% of all PRAME-TCR CO -CD20 CO td pp65-specific T cells were eliminated. No loss of PRAME-specific IFN-g responses were observed when T cells without CD20 suicide switch were incubated with RTX followed by complement treatment (Figures 4b and d ). These results demonstrate that after 20 min of RTX incubation followed by 90 min complement treatment at least 95% of PRAME-TCR CO -CD20 CO td pp65-specific T cells were eliminated.
In conclusion, we have demonstrated that codon optimization of both the PRAME-TCR and CD20 resulted in profound coexpression of both transgenes. This concordant expression allows the use of CD20 as both a selection marker, as well as a suicide gene resulting in selective and efficient elimination of td T cells. Elimination with RTX followed by complement treatment was highly specific for CD20 CO td T cells, and efficiently eliminated all T-cells capable of recognizing melanoma cells. We have previously demonstrated that functional reactivity of the PRAMEspecific T-cells clone correlated with PRAME mRNA expression. 21 Melanoma cells express 30-100 fold higher levels of PRAME than mature dendritic cells and proximal tubular epithelial cells. In our experiments, after a single RTX/complement treatment some T cells were still capable of recognizing PRAME peptide pulsed T2 cells expressing unphysiologically high levels of PRAME, whereas no T2 T2 + PRAME pep T2 B7 + pp65 pep MI 3046/2 PRAME -FM-6 PRAME + Figure 3 . PRAME-TCR CO -CD20 CO td T cells can be eliminated by CDC resulting in loss of PRAME-specific functionality. To test whether PRAME-TCR CO -CD20 CO T cells could be eliminated, HLA-B7 restricted CMV pp65-specific T cells were transduced with either empty vectors (mock), CD20, CD20 CO , PRAME-TCR CO -NGF-R or PRAME-TCR CO -CD20 CO , and were tested in a CDC assay either (a) after flow cytometry-based purification using either anti-NGF-R or anti-CD20 mAbs or (b, c) without further purification. (a) Purified T cells were incubated with RTX for 20 min whereafter either medium or 1:5 diluted complement was added for another 90 min. Propidium iodide (PI) was added just before flowcytometry and the percentage of CDC was calculated as follows: PI þ cells/ PI þ and PI À cells) * 100. Average percentages and s.d. of CDC of two independent experiments performed in duplicate are depicted. (b, c) To test whether the PRAME-specific reactivity could be eliminated, PRAME-TCR CO -CD20 CO td T cells were tested 1 week after transduction without further purification in a stimulation assay. Number of effector T cells tested were corrected for transduction efficiency, so that 5 Â 10 3 td T cells were tested against 2 Â 10 4 target cells. T cells were preincubated for 20 min with RTX or medium, followed by complement treatment for another 90 min. (b) PRAME-TCR CO -NGF-R or PRAME-TCR CO -CD20 CO were tested against unpulsed T2 (white bars), T2 pulsed with PRAME peptide (black bars), T2 td with HLA-B7 (T2
B7
) and pulsed with pp65 peptide (gray bars), or (c) against HLA-A2 þ PRAME À MI 3046/2 melanoma cells (white bars) or HLA-A2 þ PRAME þ FM-6 melanoma cells (black bars). Percentages indicate transduction efficiency. A representative example out of four experiments performed with two different td pp65-specific T cells is shown.
recognition of PRAME þ melanoma cells could be observed. This would imply that all td T cells capable of responding to physiological levels of PRAME are eliminated, including td T cells capable of recognizing low levels of PRAME on mature dendritic cells and proximal tubular epithelial cells. Therefore, for future Phase I/II clinical trials we will use multi-cistronic vectors encoding TCRs in combination with the codon optimized CD20 suicide switch.
MATERIALS AND METHODS

Retroviral vector construction and production of viral supernatant
Retroviral vectors and viral supernatant were generated as previously described. 4 Constructs used are: mock vectors containing NGF-R markergene only, unmodified CD20, 32 codon optimized CD20, multicistronic vector containing HA2-TCR 5 and CD20 and multi-cistronic vectors containing codon optimized and cysteine modified PRAME-TCR either coupled to NGF-R 21 or codon optimized CD20. Constructs are described in more detail in the Supplementary Information.
HLA Class I tetrameric complexes, flow cytometric analyses and cell sorting
In this study, different phycoerythrin-conjugated HLA class I tetramers were used, constructed as previously described 35 and described in more detail in the Supplementary Information. For flow cytometric analyses as well as flow cytometry-based sorting, cells were washed twice and labeled with tetramers for 1 h at 4 1C and with monoclonal antibodies for 30 min (min). Sorting was performed at 4 1C. Monoclonal antibodies used in this study are described in more detail in the Supplementary Information. Figure 4 . RTX-induced CDC results in loss of PRAME-TCR CO -CD20 CO td T cells able to recognize target cells expressing endogenously processed PRAME. To test the efficiency of RTX-induced CDC in eliminating CD20-positive T cells exhibiting PRAME-TCR reactivity, purified HLA-B7 restricted pp65-specific T cells were transduced with either PRAME-TCR CO -NGF-R (12.7% transduction efficiency) or PRAME-TCR CO -CD20 CO (7.0% transduction efficiency) and were tested 1 week after transduction without further purification in a stimulation assay. Number of effector T cells tested was corrected for transduction efficiency, either based on NGF-R expression (PRAME-TCR CO -NGF-R td T cells) or CD20 expression (PRAME-TCR CO -CD20 CO td T cells). PRAME-TCR CO -NGF-R td cells (left panels) or CD20-positive PRAME-TCR CO -CD20 CO td pp65-specific T cells (right panels) were either incubated with medium (a, c) or RTX 1 mg ml À 1 (b, d) followed by complement treatment. T cells were titrated down and tested for PRAME-specific IFN-g production. The number of td T cells tested per well is indicated. Target cells used were HLA-A2 þ T2 cells either unpulsed or pulsed with PRAME peptide (a, b) or HLA-A2 þ PRAME À MI 3046/2 or PRAME þ FM-6 melanoma cells expressing endogenously processed PRAME (c, d). A representative example out of four experiments performed with two different pp65-specific T cells is shown.
Isolation, transduction and culturing of cells
All studies were conducted with approval of the institutional review board at Leiden University Medical Center. After informed consent, virus-specific T cells were isolated by flow cytometry based cell sorting from different individuals using tetramers (495% purity). Tetramer-positive T cells were maintained in T-cells medium consisting of Iscoves modified Dulbecco's medium (Cambrex, Verviers, Belgium) with 5% human serum, 5% fetal bovine serum and 100 IU ml À 1 IL-2. T cells were restimulated every 2 weeks using irradiated allogeneic PBMC and phytohemagglutinin, as previously described, 35 and expanded. Retroviral transduction of TCRdeficient J76 cells, 36 total T cells derived from two different individuals and virus-specific T cells were performed as previously described 35 using recombinant human fibronectin fragments 37 CH-296 with minor modifications. Before adding the cells, retroviral supernatant was spinned onto Retronectin coated plates for 20 min at 3000 r.p.m. at 4 1C. td cells were analyzed for transduction efficiency and either tested directly without sorting, or were sorted based on NGF-R or CD20 expression (499% purity), and the cells were expanded in bulk. The reactivity of td T cells was analyzed against T2 cells, T2 cells loaded with peptide (1 mg ml À 1 ), HLA-A * 0201 þ PRAME þ FM-6 or HLA-A * 0201 þ PRAME À MI 3046/2 melanoma cell lines, 21 which were maintained in Iscoves modified Dulbecco's medium supplemented with 10% fetal bovine serum.
Magnetic-activated cell sorting enrichment
To enrich cell populations of interest, td cells were stained with anti-CD20 phycoerythrin-conjugated monoclonal antibodiess for 20 min at 4 1C followed by 20 min incubation with magnetic anti-phycoerythrin beads (Miltenyi Biotec, Bergisch Gladbach, Germany) following manufacturer's protocol. Cells were washed, resuspended in MACS running buffer and separated over a MACS column. The purity of the cells was confirmed by flow cytometric analysis directly and after additional culturing.
Complement-dependent cytotoxicity
To investigate the functionality of CD20 as a suicide switch, 5 Â 10 4 T cells were incubated in duplicate in 96-wells plates with or without 1 mg ml À 1 RTX in 50 ml of T-cells medium. After 20 min of incubation at RT, baby rabbit complement (Cedarlane Laboratories Limited, Hornby, ON, Canada) was added to a final volume of 100 ml in a working dilution of 1:5 and cells were incubated for another 90 min at 37 1C. Both flowcytometry and Enzymelinked immunosorbent assay were used to check viability of the T cells. For flow cytometric analysis of viability, cells preincubated with RTX and baby rabbit complement were spinned down, resuspended in phosphatebuffered saline with 2% glutathione peroxidase, and immediately before flowcytometry 2 mg ml À 1 propidium iodide was added. A minimum of 2 Â 10 4 of total events was acquired. As negative controls, samples with T cells incubated with only RTX or only complement were included. Viability was calculated as follows: (sample viability/ negative control viability) * 100%. Data were measured as mean±s.d. In some experiments, viability of td T cells was functionally tested by measuring loss of PRAMEspecific IFN-g production. After preincubation with RTX and complement, 5 Â 10
3 td T cells were tested against 2 Â 10 4 target cells. IFN-g production was measured after 18 h using standard Enzyme-linked immunosorbent assay (CLB, Amsterdam, The Netherlands). 15 Data were measured as mean±s.d.
Statistics
CD20 cell surface expression of td J76 and virus-specific T cells were evaluated in a paired fashion by use of the Students' t-test. Reported P-values are two sided and were considered statistically different if o0.01.
